Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

  • Revenue in USD (TTM)45.78bn
  • Net income in USD13.65bn
  • Incorporated1994
  • Employees100.41k
  • Location
    Sanofi SA54 rue la BoetiePARIS 75008FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
Kymab LtdAnnounced11 Jan 202111 Jan 2021Announced0.36%1.45bn
Kiadis Pharma NVAnnounced02 Nov 202002 Nov 2020Announced2.20%254.17m
Principia Biopharma IncDeal completed17 Aug 202017 Aug 2020Deal completed-7.48%3.67bn
Data delayed at least 15 minutes, as of Jan 27 2021 16:36 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Zoetis Inc6.54bn1.66bn75.91bn10.60k45.8621.0736.0911.603.483.4813.707.580.52341.296.41617,169.8013.3011.6215.4313.7169.8466.8325.4118.902.1410.020.680922.907.475.528.4620.8020.6417.02
Gilead Sciences, Inc.23.15bn1.27bn83.61bn11.80k69.314.7931.693.610.96240.962418.3013.920.38575.146.401,961,610.002.0618.072.4521.8879.0283.425.3339.313.15--0.626425.341.46-2.04-1.34-14.958.17--
Sanofi SA (ADR)45.78bn13.65bn123.88bn100.41k9.07--8.052.715.425.4218.22--------455,958.30--3.69--4.3967.6668.3728.8310.78--36.48--96.005.483.30-32.69-7.414.562.02
Bristol-Myers Squibb Co39.40bn-44.00m145.62bn30.00k--2.9016.193.70-0.1139-0.113918.0522.190.43067.147.121,313,167.00-0.03068.56-0.036911.2171.5272.59-0.071117.511.5811.080.472372.4515.8910.49-30.8911.419.712.64
Amgen, Inc.24.99bn7.35bn150.55bn23.40k20.8513.7713.966.0312.4012.4042.1418.780.40251.626.491,067,821.0011.8410.8314.2112.6776.7381.7529.4234.011.889.760.757841.54-1.623.09-6.588.74-9.2318.91
Data as of Jan 27 2021. Currency figures normalised to Sanofi SA's reporting currency: US Dollar USD

Institutional shareholders

4.14%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 30 Sep 202039.37m1.56%
Fisher Asset Management LLCas of 30 Sep 202018.62m0.74%
Fidelity Management & Research Co. LLCas of 30 Sep 202013.29m0.53%
BlackRock Investment Management LLCas of 30 Sep 20208.30m0.33%
Invesco Advisers, Inc.as of 30 Sep 20206.36m0.25%
Managed Account Advisors LLCas of 30 Sep 20205.60m0.22%
Hotchkis & Wiley Capital Management LLCas of 30 Sep 20203.53m0.14%
Strategic Advisers LLCas of 30 Sep 20203.26m0.13%
Lazard Asset Management LLCas of 30 Sep 20203.09m0.12%
Macquarie Investment Management Business Trustas of 30 Sep 20202.90m0.12%
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.